A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)-Reference-Cited by-同舟云学术

A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)

Published:2016-02-08 Issue:1 Volume:16 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Avallone Antonio,Piccirillo Maria Carmela,Aloj Luigi,Nasti Guglielmo,Delrio Paolo,Izzo Francesco,Di Gennaro Elena,Tatangelo Fabiana,Granata Vincenza,Cavalcanti Ernesta,Maiolino Piera,Bianco Francesco,Aprea Pasquale,De Bellis Mario,Pecori Biagio,Rosati Gerardo,Carlomagno Chiara,Bertolini Alessandro,Gallo Ciro,Romano Carmela,Leone Alessandra,Caracò Corradina,de Lutio di Castelguidone Elisabetta,Daniele Gennaro,Catalano Orlando,Botti Gerardo,Petrillo Antonella,Romano Giovanni M.,Iaffaioli Vincenzo R.,Lastoria Secondo,Perrone Francesco,Budillon Alfredo

Funder

Ministero della Salute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-016-2102-y

Reference46 articles.

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104–17.

2. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438(7070):967–74.

3. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358(19):2039–49.